These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15842984)

  • 21. Functional behavior of patients with conventional pacemakers undergoing cardiac resynchronization.
    Silva RT; Martinelli Filho M; Lima CE; Martins DG; Nishióka SA; Pedrosa AA; Crevelari ES; Costa R; Sosa EA; Ramires JA
    Arq Bras Cardiol; 2008 Feb; 90(2):138-43. PubMed ID: 18392387
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac resynchronization therapy improves heart rate profile and heart rate variability of patients with moderate to severe heart failure.
    Fantoni C; Raffa S; Regoli F; Giraldi F; La Rovere MT; Prentice J; Pastori F; Fratini S; Salerno-Uriarte JA; Klein HU; Auricchio A
    J Am Coll Cardiol; 2005 Nov; 46(10):1875-82. PubMed ID: 16286175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual-site left ventricular cardiac resynchronization therapy.
    Padeletti L; Colella A; Michelucci A; Pieragnoli P; Ricciardi G; Porciani MC; Tronconi F; Hettrick DA; Valsecchi S
    Am J Cardiol; 2008 Dec; 102(12):1687-92. PubMed ID: 19064025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac resynchronization therapy improves exercise heart rate recovery in patients with heart failure.
    Okutucu S; Aytemir K; Evranos B; Aksoy H; Sabanov C; Karakulak UN; Kaya EB; Kabakci G; Tokgozoglu L; Ozkutlu H; Oto A
    Europace; 2011 Apr; 13(4):526-32. PubMed ID: 21076146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of cardiac resynchronization therapy on exercise performance, functional capacity, and quality of life in systolic heart failure with QRS prolongation: COMPANION trial sub-study.
    De Marco T; Wolfel E; Feldman AM; Lowes B; Higginbotham MB; Ghali JK; Wagoner L; Kirlin PC; Kennett JD; Goel S; Saxon LA; Boehmer JP; Mann D; Galle E; Ecklund F; Yong P; Bristow MR
    J Card Fail; 2008 Feb; 14(1):9-18. PubMed ID: 18226768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.
    Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Six-minute walking test predicts long-term cardiac death in patients who received cardiac resynchronization therapy.
    Castel MA; Méndez F; Tamborero D; Mont L; Magnani S; Tolosana JM; Berruezo A; Godoy M; Sitges M; Vidal B; Roig E; Brugada J
    Europace; 2009 Mar; 11(3):338-42. PubMed ID: 19136491
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Time course of effects of cardiac resynchronization therapy in chronic heart failure: benefits in patients with preserved exercise capacity.
    Piepoli MF; Villani GQ; Corrà U; Aschieri D; Rusticali G
    Pacing Clin Electrophysiol; 2008 Jun; 31(6):701-8. PubMed ID: 18507542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac resynchronization with sequential biventricular pacing for the treatment of moderate-to-severe heart failure.
    León AR; Abraham WT; Brozena S; Daubert JP; Fisher WG; Gurley JC; Liang CS; Wong G;
    J Am Coll Cardiol; 2005 Dec; 46(12):2298-304. PubMed ID: 16360062
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure.
    Foley PW; Muhyaldeen SA; Chalil S; Smith RE; Sanderson JE; Leyva F
    Europace; 2009 Apr; 11(4):495-501. PubMed ID: 19307283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiac efficiency and oxygen consumption measured with 11C-acetate PET after long-term cardiac resynchronization therapy.
    Lindner O; Sörensen J; Vogt J; Fricke E; Baller D; Horstkotte D; Burchert W
    J Nucl Med; 2006 Mar; 47(3):378-83. PubMed ID: 16513605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the effects of cardiac resynchronization therapy in patients with class II versus class III and IV heart failure (from the InSync/InSync ICD Italian Registry).
    Landolina M; Lunati M; Gasparini M; Santini M; Padeletti L; Achilli A; Bianchi S; Laurenzi F; Curnis A; Vincenti A; Valsecchi S; Denaro A;
    Am J Cardiol; 2007 Sep; 100(6):1007-12. PubMed ID: 17826388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluation (MIRACLE-ICD) trials.
    Pires LA; Abraham WT; Young JB; Johnson KM;
    Am Heart J; 2006 Apr; 151(4):837-43. PubMed ID: 16569543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of implantable sensors for management of heart failure.
    Kadhiresan K; Carlson G
    Stud Health Technol Inform; 2004; 108():219-27. PubMed ID: 15718650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endomyocardial upregulation of beta1 adrenoreceptor gene expression and myocardial contractile reserve following cardiac resynchronization therapy.
    Vanderheyden M; Mullens W; Delrue L; Goethals M; Verstreken S; Wijns W; de Bruyne B; Bartunek J
    J Card Fail; 2008 Mar; 14(2):172-8. PubMed ID: 18325466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rationale, design, and baseline characteristics of a Program to Assess and Review Trending INformation and Evaluate CorRelation to Symptoms in Patients with Heart Failure (PARTNERS HF).
    Whellan DJ; O'Connor CM; Ousdigian KT; Lung TH;
    Am Heart J; 2008 Nov; 156(5):833-9, 839.e2. PubMed ID: 19061695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced atrial tachyarrhythmia susceptibility after upgrade of conventional implanted pulse generator to cardiac resynchronization therapy in patients with heart failure.
    Yannopoulos D; Lurie KG; Sakaguchi S; Milstein S; Ermis C; VanHeel L; Benditt DG
    J Am Coll Cardiol; 2007 Sep; 50(13):1246-51. PubMed ID: 17888841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How does cardiac resynchronization therapy improve exercise capacity in chronic heart failure?
    Middlekauff HR
    J Card Fail; 2005 Sep; 11(7):534-41. PubMed ID: 16198250
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of heart rate during exercise for response to cardiac resynchronization therapy.
    Maass AH; Buck S; Nieuwland W; Brügemann J; van Veldhuisen DJ; Van Gelder IC
    J Cardiovasc Electrophysiol; 2009 Jul; 20(7):773-80. PubMed ID: 19207785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atrial fibrillation in recipients of cardiac resynchronization therapy device: 1-year results of the randomized MASCOT trial.
    Padeletti L; Muto C; Maounis T; Schuchert A; Bongiorni MG; Frank R; Vesterlund T; Brachmann J; Vicentini A; Jauvert G; Tadeo G; Gras D; Lisi F; Dello Russo A; Rey JL; Boulogne E; Ricciardi G;
    Am Heart J; 2008 Sep; 156(3):520-6. PubMed ID: 18760135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.